Information about Pomalidomide
Pomalidomide is an immunomodulatory and antineoplastic agent that is used in the therapy of multiple myeloma.
Liver safety of Pomalidomide
Pomalidomide, like the structurally related agents thalidomide and lenalidomide, is associated with a low rate of serum aminotransferase elevations during therapy and has been implicated in causing rare instances of clinically apparent liver injury which can be severe.
Mechanism of action of Pomalidomide
Pomalidomide (pom" a lid' oh mide) is a thalidomide derivative (3-amino-thalidomide) similar to lenalidomide that has potent immunomodulatory and antiangiogenic activity and is used as an antineoplastic agent. In vitro and in animal models, pomalidomide has greater antineoplastic activity and is less toxic than thalidomide and lenalidomide, but direct comparisons of these agents in humans have not been done.
FDA approval information for Pomalidomide
Pomalidomide was approved for use (combined with dexamethasone) in the United States for refractory multiple myeloma in 2015.
Clinical use of Pomalidomide
Pomalidomide has also been used on an experimental basis for myelofibrosis and other myeloproliferative disorders.
Brand name for Pomalidomide
Pomalidomide is available in capsules of 1, 2, 3 and 4 mg under the brand name Pomalyst.
Dosage and administration for Pomalidomide
The recommended dose for multiple myeloma is 4 mg daily for 21 days in cycles of 28 days indefinitely or until there is disease progression or intolerance. Its use is restricted because of teratogenicity and strict adherence to birth control (for both men and women) is required.
Side effects of Pomalidomide
Side effects of pomalidomide are common and similar to those of thalidomide and lenalidomide and include sedation, dizziness, orthostatic hypotension, neutropenia, thrombocytopenia, anemia, peripheral neuropathy and venous thromboembolism (for which reason it is usually given with antiplatelet agents such as aspirin or with anticoagulation).